HCPCS Code Details - C9073

HCPCS Level II Code
Temporary Codes for Use with Outpatient Prospective Payment System
HCPCS Code C9073
Description

Long description:
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Short description:
Brexucabtagene autoleucel ca

HCPCS Modifier1
HCPCS Pricing indicator 53 - Statute
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Statute number 1833(T)
Coverage code D - Special coverage instructions apply
BETOS2 code O1E - Other drugs
HCPCS Action code D - Discontinue procedure or modifier code
Type of service 9 - Other medical items or services
Effective date Effective Apr 01, 2021
Date added Added Jan 01, 2021
Termination date Mar 31, 2021
HCPCS Coding Procedures
  HCPCS Code C9073 has been discontinued effective Apr 01, 2021.

HCPCS Modifiers

In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.

Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
NU” identifies the hospital bed as new equipment

See also

  • HCPCS C9072 · Injection, immune globulin (asceniv), 500 mg

  • HCPCS Q2053 · Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • HCPCS C9074 · Injection, lumasiran, 0.5 mg


1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”